ABEO
ABEONA THERAPEUTICS INC.
NASDAQ · Healthcare · Biotechnology · US
$4.35
−4.61%Year over year
Reported trailing growth
- Revenue
- +6280.0%
- EBITDA
- —
- EBIT
- -12.2%
- EPS
- —
- Free cash flow
- -14.4%
- Operating cash flow
- -15.9%
Forward estimates
Based on analyst estimates
- Revenue
- +264.6%
- EBITDA
- +88.4%
- EPS
- +69.3%
Three-year CAGR
- Revenue
- +60.3%
- EBITDA
- +238.8%
- EBIT
- -39.3%
- Net income
- +211.7%
- EPS
- +186.5%
- Free cash flow
- -44.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026